BCM
SMMT icon

Bridgeway Capital Management’s Summit Therapeutics SMMT Stock Holding History

Bridgeway Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-89,100
Closed -$379K – 1423
2022
Q4 		$379K Hold
89,100
– – 0.01% 948
2022
Q3 		$106K Hold
89,100
– – ﹤0.01% 1260
2022
Q2 		$89K Sell
89,100
-40,000
-31% -$56.1K ﹤0.01% 1239
2022
Q1 		$316K Buy
+129,100
New +$325K 0.01% 1062

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

Bridgeway Capital Management's SMMT Position: Q1 2023 in Review

Bridgeway Capital Management sold out of Summit Therapeutics (SMMT) in Q1 2023, closing a stake of 89,100 shares — an estimated $379K sold.

Bridgeway Capital Management first reported a position in SMMT in Q1 2022 and held it in 4 quarters. The position peaked at $379K in Q4 2022. 91 funds tracked by Wall St. Rank hold SMMT as of Q1 2023.

  • Bridgeway Capital Management reported no remaining Summit Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Bridgeway Capital Management sold 89,100 Summit Therapeutics shares in Q1 2023, an estimated $379K.
  • Bridgeway Capital Management first reported a position in Summit Therapeutics in Q1 2022 and held it in 4 quarters.
  • Bridgeway Capital Management's Summit Therapeutics position peaked at $379K in Q4 2022.
  • 91 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2023.

Based on Bridgeway Capital Management's 13F filing for Q1 2023, filed 15 May 2023.